Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aptevo Therapeutics Inc. - Common Stock (NQ:APVO)

4.969 +0.159 (+3.30%)
Streaming Delayed Price Updated: 12:21 PM EDT, Apr 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aptevo Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Aptevo Provides State of the Business Report and 2025 Financial Results
Via ACCESS Newswire
News headline image
Aptevo to Participate in March 2026 Conferences
Via ACCESS Newswire
News headline image
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
Via ACCESS Newswire
News headline image
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025
Via ACCESS Newswire
News headline image
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update
Via ACCESS Newswire
News headline image
Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter
Via ACCESS Newswire
News headline image
TOMI Environmental Solutions (NASDAQ: TOMZ): The Next Era of Disinfection Technology – More Stocks Inside
Via AB Newswire
News headline image
Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML
Via ACCESS Newswire
News headline image
Foremost Clean Energy and Aptevo Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules
Via ACCESS Newswire
News headline image
Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update
Via ACCESS Newswire
News headline image
Aptevo Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules
Via ACCESS Newswire
News headline image
Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules
Via ACCESS Newswire
News headline image
Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML
Via ACCESS Newswire
News headline image
Aptevo Participating in the BIO International Convention
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
News headline image
Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
News headline image
$2 Stocks to Watch: PNPN.V, TIVC, APVO, OSRH, PRSO Biotech Breakthroughs, MedTech Momentum Metallic Metals Power Play & Signal Innovation
Via AB Newswire
Topics Intellectual Property
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.